BioTime Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
ALAMEDA, Calif.--(BUSINESS WIRE)--$BTX--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell therapy transplant currently in development for the treatment of dry form age-related macular degeneration (dry-AMD). The data were presented at the 2018 American Academy of Ophthalmology Annual